lobbying_activities: 2777686

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2777686	6b071f1c-f9ea-4637-aa9a-b314d51e7279	Q1	MARSHALL & POPP, LLC	401105121	AMGEN USA INC.	2022	first_quarter	PHA	Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B and ESRD.	Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2022-04-18T06:41:42-04:00